Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, ACC017. This molecule is now cleared for assessment as a potential treatment for HIV-1 infection when used in combination with other antiretroviral drugs.
ACC017 is a human immunodeficiency virus (HIV) integrase strand transfer inhibitor, designed to effectively block the integration of the HIV genome into the host genome DNA by inhibiting HIV integrase activity. Pre-clinical studies have demonstrated that ACC017 possesses a distinct mechanism of action, exhibits potent antiviral effects, and shows synergistic effects when used in conjunction with other antiretroviral drugs. The drug has also been found to have a substantial safety window, indicating its potential safety profile in clinical use.- Flcube.com
